Universal-Beteiligungs- und Servicegesellschaft
AKBA icon

Universal-Beteiligungs- und Servicegesellschaft’s Akebia Therapeutics AKBA Stock Holding History

Universal-Beteiligungs- und Servicegesellschaft’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,107
Closed -$56.5K – 2069
2025
Q4 		$56.5K Buy
+35,107
New +$73.5K ﹤0.01% 2035

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Universal-Beteiligungs- und Servicegesellschaft's AKBA Position: Q1 2026 in Review

Universal-Beteiligungs- und Servicegesellschaft sold out of Akebia Therapeutics (AKBA) in Q1 2026, closing a stake of 35,107 shares — an estimated $56.5K sold.

Universal-Beteiligungs- und Servicegesellschaft first reported a position in AKBA in Q4 2025 and held it in 1 quarter. The position peaked at $56.5K in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Universal-Beteiligungs- und Servicegesellschaft reported no remaining Akebia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Universal-Beteiligungs- und Servicegesellschaft sold 35,107 Akebia Therapeutics shares in Q1 2026, an estimated $56.5K.
  • Universal-Beteiligungs- und Servicegesellschaft first reported a position in Akebia Therapeutics in Q4 2025 and held it in 1 quarter.
  • Universal-Beteiligungs- und Servicegesellschaft's Akebia Therapeutics position peaked at $56.5K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Universal-Beteiligungs- und Servicegesellschaft's 13F filing for Q1 2026, filed 11 May 2026.